Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Checkpoint Inhibitors in NSCLC

March 18th 2016

Less Common Mutations in Lung Adenocarcinoma

March 18th 2016

ALK-Positive Lung Cancer

March 18th 2016

Emerging Agents for Advanced EGFR+ Lung Cancer

March 18th 2016

Treatment of Relapsed EGFR-Mutant Adenocarcinoma

March 18th 2016

Upfront EGFR-Targeted Therapy

March 18th 2016

Second-Line Therapies for Non-Driver NSCLC

March 18th 2016

Chemotherapy for Advanced Lung Cancer

March 18th 2016

The Future of Biomarker Testing in Lung Cancer

March 18th 2016

PD-L1 Testing in Advanced Lung Cancer

March 18th 2016

Practical Advice on Molecular Testing in Lung Cancer

March 18th 2016

Importance of Molecular Testing in Lung Cancer

March 18th 2016

Combination Therapy Paves the Way Forward for CTLA-4 Antibodies

February 29th 2016

New research is carving out a role for ipilimumab and a second CTLA-4-targeting drug, tremelimumab, as combination therapy with potential in a variety of solid tumors. In addition to combinations with other immune checkpoint inhibitors, the agents are being evaluated across a breadth of other strategies.

Need for Dynamic, Predictive Biomarkers Remains Pressing

February 17th 2016

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.

Sequencing Decisions in Relapsed/Refractory Colorectal Cancer

February 12th 2016

The Role of TAS-102 in Metastatic Colorectal Cancer

February 12th 2016

Regorafenib in Advanced Colorectal Cancer: Dosing Strategies

February 12th 2016

Second-Line Therapy Options in mCRC

February 12th 2016

Considering Maintenance Therapy in mCRC

February 12th 2016

Optimizing Frontline Chemotherapy in mCRC

February 12th 2016